Literature DB >> 27086986

Assessment of Treatment Side Effects and Quality of Life in People with Epilepsy.

Benjamin N Blond1, Kamil Detyniecki1, Lawrence J Hirsch2.   

Abstract

Epilepsy impairs quality of life in physical, psychological, cognitive, social, and occupational domains. In people who are not seizure free, depression and adverse medication effects have a predominant role in determining quality of life. The assessment of these factors and other comorbidities is essential for maximizing quality of life in epilepsy. There are multiple tools available to assess medication effects and quality of life in a structured format. Such tools can provide superior assessments and allow clinicians to have a greater impact on their patients' quality of life.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adverse medication effects; Depression; Epilepsy; Quality of life; Structured assessment

Mesh:

Substances:

Year:  2016        PMID: 27086986     DOI: 10.1016/j.ncl.2015.11.002

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  8 in total

1.  Epilepsy and quality of life: what does really matter?

Authors:  Mario Tombini; Giovanni Assenza; Livia Quintiliani; Lorenzo Ricci; Jacopo Lanzone; Vincenzo Di Lazzaro
Journal:  Neurol Sci       Date:  2021-01-15       Impact factor: 3.307

Review 2.  The ATP-Gated P2X7 Receptor As a Target for the Treatment of Drug-Resistant Epilepsy.

Authors:  Edward Beamer; Wolfgang Fischer; Tobias Engel
Journal:  Front Neurosci       Date:  2017-02-02       Impact factor: 4.677

3.  Medication-Related Quality of Life in Thai Epilepsy Patients.

Authors:  Phantipa Sakthong; Bavornpat Suriyapakorn
Journal:  J Epilepsy Res       Date:  2019-12-31

4.  Zebrafish-Based Discovery of Antiseizure Compounds from the North Sea: Isoquinoline Alkaloids TMC-120A and TMC-120B.

Authors:  Daniëlle Copmans; Sara Kildgaard; Silas A Rasmussen; Monika Ślęzak; Nina Dirkx; Michèle Partoens; Camila V Esguerra; Alexander D Crawford; Thomas O Larsen; Peter A M de Witte
Journal:  Mar Drugs       Date:  2019-10-25       Impact factor: 5.118

5.  The Impact of Oral-Gut Inflammation in Cerebral Palsy.

Authors:  Ana Cristina Fernandes Maria Ferreira; Ryan J Eveloff; Marcelo Freire; Maria Teresa Botti Rodrigues Santos
Journal:  Front Immunol       Date:  2021-02-25       Impact factor: 7.561

6.  Efficacy comparison of oxcarbazepine and levetiracetam monotherapy among patients with newly diagnosed focal epilepsy in China: A multicenter, open-label, randomized study.

Authors:  Haoyue Zhu; Xuejun Deng; Li Feng; Yajun Lian; Xiong Han; Zhenli Guo; Yulan Gou; Yuanmin Du; Longshan Xie; Dongai Yao; Yonghong Liu; Qiang Wu; Song Lan; Kaisheng Liu; Peiyan Zhan; Xiahong Wang; Jingxia Dang; Yunqi Hou; Keqiang Chen; Yulan Zhu; Yuliang Shi; Yunli Yu; Bo Xiao; Suiqiang Zhu; Hongmei Meng
Journal:  CNS Neurosci Ther       Date:  2022-04-15       Impact factor: 7.035

7.  Design of composite measure schemes for comparative severity assessment in animal-based neuroscience research: A case study focussed on rat epilepsy models.

Authors:  Roelof Maarten van Dijk; Ines Koska; Andre Bleich; Rene Tolba; Isabel Seiffert; Christina Möller; Valentina Di Liberto; Steven Roger Talbot; Heidrun Potschka
Journal:  PLoS One       Date:  2020-05-15       Impact factor: 3.240

8.  Assessment of Quality of Life of Epileptic Patients in Ethiopia.

Authors:  Esileman Abdela Muche; Mohammed Biset Ayalew; Ousman Abubeker Abdela
Journal:  Int J Chronic Dis       Date:  2020-01-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.